Trametinib dosing plan for BRAF-negative juvenile cancer
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This Phase 2 trial tests whether trametinib can work in children or teens with a tumor that does not have BRAF mutations. It also studies the best timing and dose, especially after prior treatments have not worked or the disease came back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor tests negative for BRAF mutations (in tumor tissue and/or blood DNA), or you had BRAF-positive disease but did not respond to vemurafenib
- Your cancer must have not responded to prior therapy or has come back/progressed (or involves a high-risk organ, or there are CNS changes on MRI)
- You (and your guardian) can sign consent to take part, including consent for trametinib treatment
- If you could become pregnant or cause pregnancy: you must use effective birth control during trametinib and for at least 1 year after stopping
- You must be able to take part in the HISTIOGEN trial as well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests the medicine vemurafenib in children with refractory juvenile histiocytosis that has a BRAF mutation. It aims to find a better schedule (timing and dose) for treatment when standard therapies haven’t worked or the disease has come back.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
Hear when a new Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.